Immune checkpoint blockade (ICB) and adoptive cell therapies (ACT) with antigen-receptor gene-engineered T cells have been shown to be successful for a limited number of patients with solid tumors. Responders to ICB therapy typically have T cell-inflamed tumors. Thus, it is important to develop strategies that convert non-T cell-inflamed tumors to T cell-inflamed tumors. Although chimeric antigen receptor transduced T (CAR-T) cell therapy targeting hematological malignancies demonstrated durable clinical responses, the success of gene-engineered T cell therapies in solid tumors is hampered by a lack of unique antigens, antigen loss in cancer cells, and the immune-suppressive tumor microenvironment (TME) of solid tumors. However, gene-engineered T cells possess strong killing activity and cytokine production capacity, which can induce antigen spreading and modulate the TME of non-T cell-inflamed tumors seen in non-responders to ICB therapy. Immune responses against cancer are highly heterogeneous, not only between tumor types, but also within a patient or between different patients with the same type of cancer, indicating that personalized immunotherapy should be employed, based on the immune status of the individual patient. Here, we offer our perspective for personalized combination immunotherapy for solid tumors based on ACT and ICB therapies.
Immune checkpoint blockade therapies
Cytotoxic T cells can specifically recognize tumor antigen (tumor Ag) and eliminate cancers 1−4) . As demonstrated by recent evidence from study of immune checkpoint blockade (ICB) and adoptive T cell therapies, an entirely immunologic approach can treat a wide range of human cancers. ICB therapies, which use monoclonal antibodies (mAbs) that target inhibitory immune checkpoint molecules such as cytotoxic T lymphocyteassociated protein 4 (CTLA-4) 5) and programmed cell death protein 1 (PD-1)/programmed cell death-ligand protein 1 (PD-L1) 6) , have demonstrated durable clinical responses in various cancers, including melanoma 7, 8) , lung cancer 8, 9) , renal cell carcinoma 8, 10) , bladder cancer 11) , ovarian cancer 12) , triple-negative breast cancer 13) , gastric cancer 14) , Hodgkin's lymphoma 15) , and gastrointestinal and endometrial cancers associated with defects in DNA mismatch repair 16) . In melanoma, lung cancer, and renal cell carcinoma, clinical response rates as high as 20−30%
have been reported 8, 9) . The observed anti-tumor responses were associated with the activation and expansion of tumor Ag-specific T cells 17, 18) , and responding patients showed high pre-treatment tumor infiltration of T cells compared to non-responding patients 19) . This evidence suggests that conversion of non-T cell-inflamed tumors to T cell-inflamed tumors would improve response to ICB therapies.
Adoptive cell therapies
T cells are considered the final effectors of immune-mediated cancer regression, hence direct administration of tumor Ag-specific T cells has been developed into adoptive T cell therapies (ACT) 20) (Fig. 1) . To broaden the efficacy of ACT, the antigens recognized by TILs have been studied extensively.
A recent report has demonstrated that mutated antigens in a non-melanoma epithelial cancer (i.e. gastrointestinal cancer) can give rise to immune responses, despite the low number of nonsynonymous somatic mutations in these cancers 3) . While TILs can be grown in vitro from virtually all tumors, TILs that demonstrate a clinical response have only been produced from melanomas 20) .
Gene-engineered cell therapies
Progress in genetic engineering technologies has enabled the efficient generation of antigen-receptor gene-
engineered T cells, including T cell receptor transduced T (TCR-T) cells and chimeric antigen receptor transduced
T (CAR-T) cells (Fig. 1) . Use of gene-engineered T cells obviates the requirement for surgery because these T cells can be isolated from blood samples, and viral or non-viral transduction of receptors confers tumor Ag specificity 23) .
As the same antigen receptor can be used for a large . . However, in a study using affinity-enhanced TCR against HLA-A*01-restricted MAGE-A3, 2 patients with melanoma and myeloma developed cardiogenic shock and died within a few days of T-cell infusion. This adverse effect was caused by recognition of an unrelated peptide derived from cardiomyocytes by the affinityenhanced TCR 30, 31) .
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Fig. 2. Prospects for combination adoptive immunotherapies
The immune status of tumors can be categorized into four types, based on mutation-derived immunogenicity, mainly passenger mutations, and mutation-derived immunosupression, mainly driver mutations. The tumor shown in panel A possesses a large amount of imunogenic mutations; hence, tumor Ag-specific T cells have infiltrated strongly and immune checkpoint blockade (ICB) therapies would be effective. In contrast, the tumor shown in panels C and D possesses a highly immunosupressive tumor microenvironment (TME), hence modulation of the TME would be needed. Because the tumor in panel B shows very weak immunognicity, treatment for enhancement of immune recognition (e.g., immunogenic cell death) would be needed. Because patient immune status is highly heterogeneous, personalized combination immunotherapy should be considered.
infinite antigenic diversity and operate at affinities in the nanomolar range 34, 35) . As an additional advantage, the signaling domain of CAR constructs can be modulated to exhibit various T cell functions, including expansion, survival, cytokine secretion, tissue-selectivity, and safety 36−40) .
Clinical trials of CAR-T cell therapies
Many clinical trials of CD19-specific CAR-T cell .
This case might lead to relaxation of the restriction of target antigens for gene-engineered T cell therapies.
Immunosuppressive TME and ACT therapies
The immunosuppressive status of the tumor microenvironment (TME) is a major problem in cancer immunotherapies, as it reduces the anti-tumor effects of immunotherapies. Two types of immunosuppression mechanisms operate in the TME 53, 54) . One is tumor- Wnt-β-catenin signaling pathway 55, 56) , the MAPK signaling pathway 57, 58) , the JAK-STAT3 signaling pathway 57, 59) , and the NF-κB signaling pathway 60) . . Based on current knowledge, it is conceivable that combination therapies of ACT with inhibition of the activated oncogene pathways using small molecule inhibitors could work synergistically to exhibit anti-tumor effects through mechanisms that restore T-cell infiltration. In a recent study, BRAF inhibitors improved the anti-tumor activity of ACT in mouse models 62) .
The latter mechanism, local adaptive immuno- . In ACT therapies, adaptive immunosuppression can theoretically occur, and it is also conceivable that combination therapies of ACT with ICB therapies could be effective through restoration of T-cell function.
Modulation of the TME by gene-engineered T cell therapies
Gene-engineered T cell therapies, which typically target monoclonal antigens, have a disadvantage compared to TIL therapies, which use polyclonal TILs.
This disadvantage was exemplified by a CD19-specific CAR-T cell therapy, which led to the loss of CD19 expression in leukemia cells 44) . Although it might be not easy to cure bulky tumors using only gene-engineered T cell therapies, their strong killing and cytokine production abilities could be employed for tumor Ag releasing and modulation of the immunosuppressive TME. The evidence for contribution of antigen spreading to favorable outcomes in CAR-T cell therapy was suggested in an immunocompetent mouse model. This study showed that the cured mice which were treated with ACT of murine EGFRvIII-specific CAR-T cell therapy did not develop tumors upon rechallenge with EGFRvIII negative matched tumor 66) . This study suggests that the strong anti-tumor abilities of gene-engineered T cell therapies could potentially trigger anti-tumor immune reaction and convert the non-T cell-inflamed TME seen in ICB non-responders to the T cell-inflamed TME.
CD4 + CAR-T cell therapies
Because CD8 . Antigen-specific Th17 cells differentiated in vitro showed antitumor activity against murine B16 melanoma stronger than that of Th1 cells 77, 78) . These Th17 cells promoted production , and preexisting effector T cell infiltration 19) . Notably, immune
infiltrates are highly heterogeneous, not only between tumor types, but also within a patient or between different patients with the same cancer type, indicating that personalized immunotherapy should be employed based on the immune status of the individual patient. Thus, we
propose classification of tumors into four groups, on the basis of their immunogenicity and immune suppression in the TME 82) (Fig. 2) . pression may be operating in the TME of these patients, oncogene pathway-targeted therapies, TME cytokine modulation by ACT of CD4 + CAR-T cells 74) , or other immune suppression blockades could be used to convert the TME from C to B (arrow 2). In patients with moderate pre-existing anti-tumor T cells, because of tumor immunogenicity and strong tumor-intrinsic immune suppression (shown in Panel D), the immunosuppressive TME needs to be modulated. In these patients, oncogene pathway-targeted therapies, other immune suppression blockades, or TIL therapies could be used to convert TME from D to A (arrow 3). Overall, personalized combination immunotherapy should be considered for improvement of cancer immunotherapy.
